摘要
目的:观察Rho激酶抑制剂法舒地尔对急性缺血性卒中患者血清C-反应蛋白(CRP)含量和转归的影响。方法:52例确诊急性缺血性卒中并在72 h内接受治疗的住院患者,根据入院时斯堪的纳维亚卒中量表(SSS)评分和一般情况进行配对,随机分入法舒地尔组和丁咯地尔组。法舒地尔组予盐酸法舒地尔60 mg,静脉滴注,2次/d(年龄>70岁者30 mg,静脉滴注,3次/d);丁咯地尔组予盐酸丁咯地尔100 mg,静脉滴注,1次/d。两组疗程均为14 d。选择同期同龄健康体检人群26例作为对照组。所有患者于确诊次日清晨测定空腹血清CRP含量,并在治疗结束时复查SSS评分和血清CRP含量。CRP含量应用TurboxR特定蛋白分析系统(芬兰)以散射比浊法进行测定。结果:健康对照组血清CRP含量为(13.47±4.54)mg/L,略高于正常水平。丁咯地尔组和法舒地尔组治疗前CRP含量分别为(28.24±8.83)和(31.95±12.95)mg/L,显著高于对照组(P<0.001)。丁咯地尔组治疗后血清CRP含量为(24.10±10.07)mg/L,较治疗前有下降的趋势,但无显著差异;法舒地尔组治疗后为(15.10±3.92)mg/L,较治疗前显著降低(P<0.001),与丁咯地尔组也有显著差异(P<0.05)。丁咯地尔组治疗后SSS评分为34.7±5.2,较治疗前(25.8±8.2)显著增高(P<0.05)。法舒地尔组治疗后SSS评分为47.6±6.1,较治疗前(26.3±7.2)显著增高(P<0.001),与丁咯地尔组治疗后也有显著差异(P<0.01)。结论:Rho激酶抑制剂法舒地尔可显著改善急性缺血性卒中转归,可能与其降低血清CRP含量有关。
Objective： To observe the effect of Rho kinase inhibitor fasudil on the levels of serum C-reactive protein （CRP） and outcome in patients with acute ischemic stroke. Methods： Fifty-two patients with acute ischemic stroke treated within 72 hours were randomly divided into fasudil and buflomedil groups according to Scandinavian stroke scale （SSS） score and pairmatching in general condition on admission. The patients in the fasudil group received fasudil hydrochloride 60 mg, intravenous drip, twice a day （30 rag, intravenous drip, 3 times a day in patients more than 70 years old）; the patients in the buflomedil group received buflomedil hydrochloride 100 mg, intravenous drip, once a day. The course of treatment was 14 days in both groups. Twenty-six normal subjects with the same age during the study period were selected as control group. Fasting serum levels of CRP were measured in all patients the next morning after the confirmed diagnosis, and SSS scores and levels of serum CRP were reexamined at the end of treatment, The levels of CRP were measured by scatter turbidimetry with TurboxR special protein analysis system （Finland）. Results： The level of serum CRP was 13.47 ± 4. 54 mg/L in the control group, and it was slightly higher than normal level. The levels of serum CRP before the treatment in the buflomedil and fasudil groups were 2.24 ± 8.83 and 31.95 ± 12.95 mg/L respectively, and they were significantly higher than that in the control group （P 〈 0.001）. The level of serum CRP in the buflomedil group was 24. 10 ± 10.07 mg/L after the treatment, and there was a trend of decrease as compared with before the treatment, but there was no significant difference; the level of serum CRP in the fasudil group was 15.10 ± 3.92 mg/L after the treatment, and it decreased significantly as cornpared with before the treat- ment, and there was also significant difference with that in the buflomedil group （P 〈0.05）. The SSS score in buflomedil group yeas 34.7 ± 5.2 after the treatment, and it increased significantly as cornpared with before the treatment （25.8 ±8.2） （P 〈0. 05）. The SSS score in the fasudil group was 47. 6 ± 6. 1 after the treatment, and it increased significantly as compared with before the treatment （P 〈 0.01 ）. It also had significant difference with that in the buflomedil group after the treatment （P 〈 0. 01 ）. Conclusions： Rho ldnase inhibitor fasudil may significantly improve the outcome of acute ischemic stroke, which may be associated with its decreasing of the levels of serum CRP.
出处
《国际脑血管病杂志》
2007年第10期735-738,共4页
International Journal of Cerebrovascular Diseases
